ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung Cancer - Radiation Therapy

February 3, 2015
This consensus statement from the European Neuroendocrine Society is based on extensive bibliographic searches and systematic review.  Surgery is the mainstay of therapy for most tumors, and includes resection of metastases when this can be accomplished in a curative manner.  Somatostatin analogues are considered first line therapy for unresectable c
February 2, 2015
The authors queried the National Cancer Data Base to assess outcomes of patients with R1 resection margins related to the presence and type of postoperative adjuvant therapy.  3.1% of over 54,000 resections had R1 margins, which negatively affected long-term survival.  Combined chemotherapy and radiation therapy improved outcomes; administration of c
January 29, 2015
This analysis of nearly 40,000 patients with inoperable early stage lung cancer explored factors associated with delivery of potentially curative conventional radiotherapy (ConvRT) or SBRT.  Treatment was less likely in blacks and hispanics.  SBRT was more likely than ConvRT in high volume and academic centers.  Overall use of SBRT, ConvRT, and no tr
October 1, 2014
Using a single institution database, the authors propensity score matched patients receiving wedge resection, wedge resection plus brachytherapy, or SBRT for early stage NSCLC.  Survival was assessed at a median of 35 mos.  Overall recurrence was higher for SBRT vs wedge (30% vs 9%), and recurrence-free and disease-free survival were better after wed
September 12, 2014
This multi-institutional phase II trial (80 patients from 17 Canadian institutions) was performed to assess if a hypofractionated accelerated radiotherapy regimen for cytohistological-proven early stage NSCLC (peripherally located T1 to T3 N0 M0) has a good local control rate.
August 9, 2014
This multiinstitutional randomized trial compared sublobar resection alone to sublobar resection with adjuvant brachytherapy in high risk patients with peripheral NSCLC <3cm.  Time to and type of local recurrence were similar between the groups.  Brachytherapy did not importantly improve local control in patients with potentially compromised margi
July 1, 2014
This single institution retrospective study compared outcomes for lobectomy and segmentectomy using propensity score matching.  For 312 pts in each group, there was no difference in logoregional or overall recurrence rates.  Operative mortality rates were similar for segmentectomy and lobectomy (1.2% vs 2.5%).  5-year surival rates were also similar
July 1, 2014
This randomized trial of high risk patients with small clinial stage I cancers randomized pts to sublobar resection with or without adjuvant brachytherapy.  The median follow-up for 222 pts was 4.4 years.  3 year survival was identical (71%) between the groups.  There was no difference in time to local recurrence.  Brachytherapy did not significantly

Pages